髓系白血病
酪氨酸激酶
癌症研究
伊马替尼
阿布勒
白血病
医学
免疫学
生物
内科学
受体
作者
Ami B. Patel,Thomas O’Hare,Michael W. Deininger
标识
DOI:10.1016/j.hoc.2017.04.007
摘要
Chronic myeloid leukemia is increasingly viewed as a chronic illness; most patients have a life expectancy close to that of the general population. Despite progress made using BCR-ABL1 tyrosine kinase inhibitors (TKIs), drug resistance via BCR-ABL1–dependent and BCR-ABL1–independent mechanisms continues to be an issue. BCR-ABL1–dependent resistance is primarily mediated through oncoprotein kinase domain mutations and usually results in overt resistance to TKIs. However, BCR-ABL1–independent resistance in the setting of effective BCR-ABL1 inhibition is recognized as a major contributor to minimal residual disease. Efforts to eradicate persistent leukemic stem cells have focused on combination therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI